RB loss promotes prostate cancer metastasis

Chellappagounder Thangavel, Ettickan Boopathi, Yi Liu, Alex Haber, Adam Ertel, Anshul Bhardwaj, Sankar Addya, Noelle Williams, Stephen J. Ciment, Paolo Cotzia, Jeffry L. Dean, Adam Snook, Chris McNair, Matt Price, James R. Hernandez, Shuang G. Zhao, Ruth Birbe, James B. McCarthy, Eva A. Turley, Kenneth PientaFelix Y. Feng, Adam P. Dicker, Karen E. Knudsen, Robert B. Den

Research output: Contribution to journalArticle


RB loss occurs commonly in neoplasia but its contributions to advanced cancer have not been assessed directly. Here we show that RB loss in multiple murine models of cancer produces a prometastatic phenotype. Gene expression analyses showed that regulation of the cell motility receptor RHAMM by the RB/E2F pathway was critical for epithelial- mesenchymal transition, motility, and invasion by cancer cells. Genetic modulation or pharmacologic inhibition of RHAMM activity was sufficient and necessary for metastatic phenotypes induced by RB loss in prostate cancer. Mechanistic studies in this setting established that RHAMM stabilized F-actin polymerization by controlling ROCK signaling. Collectively, our findings show how RB loss drives metastatic capacity and highlight RHAMM as a candidate therapeutic target for treating advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)982-995
Number of pages14
JournalCancer Research
Issue number4
Publication statusPublished - Feb 15 2017


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thangavel, C., Boopathi, E., Liu, Y., Haber, A., Ertel, A., Bhardwaj, A., ... Den, R. B. (2017). RB loss promotes prostate cancer metastasis. Cancer Research, 77(4), 982-995. https://doi.org/10.1158/0008-5472.CAN-16-1589